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1. Introduction
1.1. Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Multiple sclerosis (MS) is a devastating neuroinflammatory disease that affects around 1
million people in the United State alone (1) and it is the most common neurological disability in
young adults (2). In MS, the immune system attacks the myelin sheaths that cover and
protect nerve fibers, causing improper communication or complete loss of
communication between the brain and the rest of the body. This neuronal damage is a direct
result of the immune cells inability to discern between self and non-self, causing what is known
as an autoimmune reaction. It is this malfunction that mediates the destructive response
of the immune cells. Allowing them to target otherwise healthy tissues within the central nervous
system (CNS) causing increased inflammation, scar tissue and brain lesions to form. Within
months of the first immune attack, lesions can be observed by magnetic resonance imaging
(MRI), which is the main method currently used for MS diagnosis and monitoring (3). Although
natural remyelination can occur, the process becomes less efficient as the disease progresses (4).
This demyelination occurs when peripheral immune cells cross the blood-brain barrier (BBB)
and penetrate in the parenchyma of the brain and spinal cords of patients. These infiltrated cells
release cytokines which further permeabilize the blood-brain barrier and recruit inflammatory
leukocytes, allowing for demyelination and neuronal degeneration. This causes a plethora of
symptoms including initial manifestations of muscle weakness, loss of coordination,
numbness, double or blurring vision and at later stages of advancement include severe paralysis,
pain, mood disorders, depression and

disturbances in urinary, sexual and gastrointestinal functions among others, leading to a reduced
quality of life for those suffering from MS (5).
There are several different forms of MS, with Relapse-Remitting MS (RRMS) being the
most common form with around 75%-85% of people being initially diagnosed with it. RRMS
tends to unequally affect women with a 2-3 x increase in its prevalence in women. The mean
onset of RRMS is ~30 years of age and is characterized by relapses of neurological dysfunction
and exacerbations that can last weeks to months. At other times, these patients can go into
remission and show little to no symptoms. Over time, most patients with RRMS enter a phase
called non-relapsing secondary progressive MS (SPMS) which is characterized by a steady but
slow progression in neurological decline and CNS atrophy. Although not very common, in a
minority of these patients the disease assumes a relatively progressive course from the onset
which is called primary progressive MS (PPMS) and does not include relapses and remissions.
The mean age of onset of PPMS is about 10 years after initial diagnosis (~ age 40) (6). Lastly, a
very rare form of MS called Progressive-Relapsing MS (PRMS) affects ~5% of patients and is
steadily worsens from the beginning with acute relapses but no remissions (7).
The exact causes of multiple sclerosis are still unknown, but many advancements in the
understanding of the disease and the development of therapeutics have been made through the
use of laboratory models. One commonly used model is experimental autoimmune
encephalomyelitis (EAE), an animal model characterized by CNS inflammation
and demyelination, allowing for symptoms resembling some of the most prominent features of
the human disease. EAE induction in mice, rats and non-human primates is widely done in
academia and industry to help study these affects and to locate the immune mechanisms that may
be triggered during the progression of the disease.
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There are two types of ways to induce EAE in mice, through active induction or adoptive
transfer. Actively induced EAE involves the induction phase; with priming of the CD4+ T cells
using an immunization of myelin proteins or peptides emulsified in Freund’s Complete Adjuvant
(CFA). CFA is composed of heat-killed Mycobacterium tuberculosis (TB) which helps to
stimulate and prime the innate immune system. The effector phase; the activated T cells will
migrate to the CNS where they cross the BBB and contribute directly to CNS damage through
several mechanisms including the production of more proinflammatory cytokines, matrix
metalloproteinases, and reactive oxygen species (8) and subsequently induce an influx and
activation of peripheral mononuclear phagocytes (monocytes/macrophages and CNS-resident
microglia) into the CNS. Now demyelination and eventual death of CNS axons occurs through
the phagocytic activity of these activated cells. The chronic activation of microglial is a known
feature of progressive MS, and like EAE it contributes to neurodegeneration (9). In comparison,
the adoptive-transfer method induces EAE by introducing pre-activated myelin epitope-specific
CD4+ T cells into the naïve animal (10). The myelin proteins or peptides used differ from which
type of mouse is being used. In SJL mice EAE can be induced using proteolipid protein (PLP),
myelin basic protein (MBP) or peptides of the immunodominant epitopes of MBP. Whereas in
C57BL/6 mice (used in these experiments), EAE is induced by an injection of the peptide
corresponding to the immunodominant epitope of MOG called (MOG35-55). Depending upon the
induction protocol used and the combination of mouse strain and myelin proteins/peptides the
disease course can take an acute, chronic progressive or relapsing remitting disease course (11).
In addition to mice receiving the myelin proteins, EAE severity can be controlled by
administering an injection containing pertussis toxin (PTX) on the same day as (MOG35-55)
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injection and another injection on the following day. With some exceptions, higher doses of PTX
increase EAE severity and lower doses lessen it (12).
In EAE induction by active immunization in C57BL/6 mice the typical onset of MS like
symptoms is 9 to 14 days after induction, with a peak of disease 3-5 days after onset for each
mouse. The peak lasts 1 to 3 days followed by partial recovery. Though in around 25% of mice
EAE severity will increase (relapse) after the initial partial recovery (13).
EAE has been able to help tease out potential causes of MS with possible contributors for
its induction and perhaps even progression range from a combination of genetic susceptibilities
(5) and environmental risk factors (14). Environmental risk factors include geography (15), low
vitamin D levels, smoking, viral exposures among others (16). Adolescent obesity has also been
identified as being a risk factor for developing MS (17), and evidence has shown that there may
be a link between diet the gut microbiota and autoimmune disorders (18).
1.2. The Gut Microbiota, EAE and MS
The microbiome is defined as the genetic material of all of the microbes contained on and
in the human body, including bacteria, archaea, eukaryotes and viruses (19). The gut microbiota
however refers to the multitude of hundreds of trillions of microbes that live in just the intestines.
The human intestines contain over 70% of the body’s microbes and the total number of microbes
contained within it is 10x more than that of the somatic and germ cells combined (20). The
unique flora will start to colonize the gut at birth and will continue to be changed and affected by
numerous factors throughout life. Besides route of delivery and being breast or bottle fed, other
factors that can change the microbiota include were one lives, lifestyle choices and notably diet.
On average a healthy human gut will contain large ratios of the bacteria phyla Firmicutes and
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Bacteroidetes (21) and contain low numbers of the phyla Proteobacteria (22). Commensal gut
microbiota perform a large range of tasks such as energy extraction through the breakdown of
otherwise indigestible polysaccharides and developing intestinal stroma and parenchyma (23).
Many beneficial effects are mediated by bacterial fermentation processes where byproducts can
be absorbed into the gastrointestinal tract and help in the regulation of many cell processes like
proliferation, differentiation and apoptosis (24). Importantly, the gut microbiota helps to
maintain the balance of both systematic and local immune responses through the synthesis and
secretion of essential vitamins (25) and stimulates the development of innate and adaptive
immune systems including the formation of the gut-associated lymphoid tissue (GALT) (26).
The gastrointestinal tract is governed by the enteric nervous system (ENS), which is a
division of the autonomic nervous system (ANS). The ENS has often been referred to as the
“second brain” because it can operate independently of the central nervous system (27).
Although it can operate without the CNS, there is much overlap between the two and evidence
shows that there is a bidirectional communication between the cells of the gut, that are guided by
the gut-microbiota, with the central nervous system. This is known as the gut-brain axis (GBA)
and this communication happens through neural, endocrine, metabolic and immune pathways.
Neural regulation happens through the microbiota of the gut secreting and regulating
neurotransmitters of the peripheral and central nervous systems such as γ -aminobutyric acid
(GABA), histamine, serotonin, melatonin and dopamine (28). Additionally, lymphocytes in the
intestines can be stimulated by local environmental changes to the gut microbiota, causing them
to release cytokines that activate downstream pathways of the endocrine and paracrine systems,
ultimately affecting the CNS. Simultaneously, the CNS can also impact the gut-microbiota
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through the secretions of catecholamines and acetylcholine which affects circuits of the enteric
nervous system (29).
Through the endocrine pathway the hypothalamus, pituitary and adrenal glands, known
as the hypothalamic-pituitary-adrenal (HPA) axis, can release glucocorticoids and
catecholamines when the body is under stress. This can increase the permeability of the gut
epithelium and cause dysbiosis which is defined as an unhealthy imbalance of the composition of
the gut microbiota (30). Glucocorticoids from the HPA can also effect the peripheral and CNS
and are often associated with autoimmune and inflammatory diseases such as rheumatoid
arthritis, inflammatory bowel disease and multiple sclerosis (31, 32).
In addition, the gut microbiota plays crucial roles in controlling the immune system.
Bacterial metabolites such as short chain fatty acids (SCFAs): butyrate, acetate and propionate,
which are produced as byproducts of bacterial fermentation of carbohydrates help to mediate
immune responses. Butyrate which is mainly produced by Firmicutes, has anti-cancer properties
by inhibiting histone deacetylase (33) and anti-inflammatory properties by reducing proinflammatory cytokines (34). It also helps to maintain blood-brain barrier (BBB) integrity (35),
modulates activity of microglia of the CNS (36) and helps generate intestinal and circulating
extrathymic regulatory T cells (Treg) (37). The gut provides ~95% of the body’s total serotonin
and it is SCFAs that regulate the synthesis of serotonin. Serotonin is able to activate afferent
nerves which are connected directly to the CNS, thus affecting gut-brain communication (38).
Abnormal gut microbiota populations can also cause the gut immune cells to release cytokines
and activate mucosal innate immune responses, causing increases in gut epithelium permeability.
This increased permeability, known as “leaky gut’ can allow bacterial antigens and LPS to enter
circulation causing system wide issues (39, 40).
6

Since multiple mechanisms guide the relationship of the gut brain axis, the gut microbiota
is also known to play a role in CNS disorders and diseases such as multiple sclerosis. Of
importance, much research shows that dietary factors leading to dysbiosis in gut microbiota
could be highly involved in immune responses and MS pathogenesis (41-46). Many of these
studies have focused on the gut microbiota within the context of EAE and show that normal gut
bacteria are required for proper induction and disease progression of EAE. For example, when
germ-free mice were induced with EAE they developed a significantly reduced severity of EAE
compared to conventionally colonized mice. They also produced lower levels of
proinflammatory cytokines IFN-γ and IL-17A and increased levels of immunosuppressive
regulatory T cells (Tregs) in the spinal cord and intestines. Yet, when segmented filamentous
bacteria (SFB), within the phylum Firmicutes that promote IL-17A, were introduced and
colonized into the gut of the germ-free mice, the proper progression and severity of EAE was
able to be restored (47). Furthermore, gut microbiota may be necessary for normal BBB
function, since germ-free mice have increased BBB permeability and decreases in properly
functioning tight junctions (35). Besides the requirement of having a functioning gut microbiota,
studies have also shown that the composition of the microbiota is also important for EAE disease
progression. When given a treatment of broad-spectrum antibiotics, mice showed reduced
susceptibility to EAE and induced changes in the peripheral lymphoid organs and in regulatory T
cell populations within the GALT (48). This was believed to be also promoted by the induction
in protective CD5(+) B cell populations (49). Additionally, when treated with Pediococcus
acidilactici, a lactic acid species, EAE was suppressed in mice by increasing protective
regulatory T cells in the gut, which produce IL-10 an anti-inflammatory cytokine (50).
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As previously mentioned, adolescent obesity is an environmental factor which has been
proposed to increase the risk of developing MS, along with having higher body mass index (BMI)
showing that diet and the gut microbiota may play a role in those who have MS (51). Much
research has been done to access any differences between the composition of gut microbiota of
those with and without MS (41, 43). Overall conclusions were that in MS patients the relative
abundances of Bacteroidaceae of the phylum Bacteroidetes were reduced when compared to
healthy individuals (52, 53), Faecalibacterium of the phylum Firmicutes were reduced (46, 52)
and the relative abundances of Ruminococcus of the phylum Firmicutes was increased (52, 53).
Although there were no whole bacterial community differences, it was observed there were
statistical differences in operational taxonomic units (OTUs) of the gut microbes which were
present. Another study using human-to-mouse fecal transplants from patients with and without
MS, showed that gut microbiota from multiple sclerosis patients triggered spontaneous EAE at
higher rates in germ-free mice, than the transplants from healthy controls did. It was postulated to
be either due to the increased activation of autoimmune effector T cells or through weakened
regulatory mechanisms (45). Moreover, a pilot study was performed in patients with relapse and
remitting MS (RRMS) where they researched the effects of diet on relapse rates, Expanded
Disability Status Scale (EDSS) scores and microbiota composition by controlling their dietary
habits of the past 12 months. They were divided into two groups, one of patients (n = 10) following
a high-vegetable/low-protein diet and a second group (n = 10) following a Standard American Diet
(SAD), which includes high consumption of red meat, processed foods and sugar. The study
reported changes on specific taxa such as an increase in the relative abundances of members of the
family Lachnospiraceae, within the phylum Firmicutes, for the individuals following highvegetable/low-protein diet. This also correlated positively with reductions in proinflammatory cell
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profiles and increases in anti-inflammatory cells, including Tregs. The pilot study, although based
on a limited number of patients, also indicated a beneficial impact on relapse rates and EDSS in
RRMS patients (54).
Other research related to obesity and diets like SAD show that high intake of
macronutrients of carbohydrates, animal based proteins, and excessive fat consumption, can
promote oxidative stress and trigger inflammation through cell signaling pathways (55). Long term
exposure to oxidative stress can cause a plethora of issues including mitochondrial dysfunction
resulting in chronic insufficiency of energy to cells, eventually leading to cell damage and death
(56). Furthermore, oxidative stress from reactive oxygen species has been shown to alter DNA
bases directly and is heavily involved in several MS pathological hallmarks such as myelin
destruction, axonal degeneration and inflammation (57).
1.3. Reactive Oxygen Species
Reactive oxygen species (ROS) are free radicals, defined as containing one or more
unpaired electrons which are then able to cause DNA damage. This term can refer to oxygen
radicals such as superoxide anion (O2-), hydroxyl (OH-), peroxyl (RO2-) and hydroperoxyl (HO2), or to nonradical oxidizing agents which can be easily converted into free radicals such as
hydrogen peroxide (H2O2), hypochlorous acid (HOCl) and ozone (O3) (58). Although ROS can
be produced through exposure to ultraviolet rays, air pollution and tobacco smoke, among other
factors, ROS production occurs during normal metabolic activity and is the result of many
important cellular processes such as enzymatic reactions, the electron transport chain in
mitochondria, signal transduction, and activation of transcription factors to alter gene
expression (58). ROS can be generated in the mitochondria, cytoplasm, endoplasmic reticulum
(ER) or on the plasma membrane. Reactive oxygen species are usually kept in check due to the
9

reducing environment within cells and by the defenses of enzymatic and non-enzymatic
systems (59). Enzymatic antioxidant substances include superoxide dismutase
(SOD), thioredoxin reductase (TR), catalase (CAT) and glutathione reductase and non-enzymatic
antioxidants such as ascorbic acid, vitamin E, glutathione (GSH) and flavonoids (60). These
cellular antioxidants inhibit ROS’s oxidative properties and prevent ROS’s unpaired electrons
from reacting with any nearby electron acceptor. Foods that are high in antioxidants, such as
leafy greens, drupes and some legumes have been shown to reduce local and systematic
inflammation (61), whereas foods mainly eaten in the Standard American Diet and other diets
with highly processed foods can stimulate oxidative stress by enhancing and increasing
inflammatory pathways and markers (62-66).
When antioxidant mechanisms are disrupted or the cell is overwhelmed by too large of an
increase in ROS concentrations, then various signaling cascades are activated, leading to
widespread DNA damage and often times neurodegenerative disorders, such as multiple
sclerosis (59). The CNS is very vulnerable to oxidative stress and dysregulation of ROS makes it
susceptible to neurodegenerative disorders. This is because for the brain to function normally,
and keep all other systems of the body active, glial cells must continuously generate pools of
ATP and therefore require more oxygen and consume more glucose, leading to the potential of
unchecked oxygen, producing free radicals (67). High ROS levels can damage the endothelium
of the brain and affect the BBB permeability (68). It has also been suggested that monocytes
interacting with the brain endothelium produce ROS and facilitate the intrusion of leukocytes
through the BBB and into the CNS (69). These leukocytes then produce harmful amounts of
ROS and induce phagocytosis of myelin by microglia that have become activated (70).
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In mice, EAE experiments show that regions of the CNS with high levels of
inflammation had increased mitochondrial dysfunction and impaired cell trafficking than
undamaged CNS areas (71). Moreover, in-vivo images of brains of EAE mice showed that ROS
from macrophages triggered dysfunction in mitochondria and caused focal axon degeneration
even in axons with otherwise intact myelin (72). Likewise, in humans with MS the periplaque
white mater around developing lesions showed significant oxidative stress which was suggested
to be a result of increased immune cell reactivity in the area. As a result of changes in energy
requirements, mitochondria increase within axons that display degeneration, and it is thought this
increased density in MS lesions is further contributing to the formation of ROS and worsening
tissue damage within the area (73).
MS lesions have also been found to contain components of what is known as the
inflammasome (74), and ROS can act as one of the signals needed for the assembly and
production of this inflammasome complex.
1.4. NLRP3 Inflammasome
The inflammasome complex is a part of the innate immune system. The dysregulation in
its activity can result in uncontrolled inflammation, underlying many chronic diseases, and
metabolic and autoimmune disorders (75). It is the inflammasome’s job to provide immune
surveillance within the cytoplasm. There are several types of inflammasomes, but one of
the most studied with regards to multiple sclerosis is the nucleotide-binding domain, leucinerich-repeat-containing family, pyrin domain containing 3 inflammasome, or more commonly
known as NLRP3 inflammasome. In fact, experiments with EAE have shown that the NLRP3
inflammasome is critical and necessary for disease development (76). This inflammasome is
comprised of protein components which assemble together into oligomers and serve as a
11

platform for recruitment, cleavage and activation of precursor forms of inflammatory cytokines
(77). NLRP3 can also initiate pyroptosis, which is a highly inflammatory form of programmed
cell death (78). The inflammasome contains the adaptor proteins procaspase-1 and apoptosisassociated speck-like protein (ASC) which help regulate its function and
activation (79). Research has shown the inflammasome appears to be activated in
two distinct steps (Fig. 1). The initial step, often called the priming step, can occur through the
binding of pathogen associated molecular patterns (PAMPs) or damage or danger-associated
molecular patterns (DAMPs) to toll-like receptors (TLRs) on the plasma membrane of immune
cells such as macrophages, monocytes, dendritic cells, lymphocytes, osteoblasts, epithelial
cells and neutrophils (79). These TLRs are then phosphorylated, starting a signaling cascade
where a IκB protein is phosphorylated by IκB kinase (IKK) complex, resulting in the release of
the now active nuclear factor- kappa B (NF-κB). Active NF-κB then leaves the cytosol
to mediate DNA binding and nuclear localization dimerization within the nucleus, to upregulates
the transcription of proinflammatory cytokines pro-Interleukin-18 (Pro IL-18) and proInterleukin-1β (Pro-IL-1β) (77). After transcription these inactive proteins remain in the cytosol
until the second step of activation occurs, which is the oligomerization of the completed NLRP3,
through the binding of NLRP3, ASC and procaspase-1. This assembly triggers the cleavage of
procaspase-1 into active caspase-1, which further processes and cleaves the now mature
proinflammatory cytokines IL-18 and IL-1β so they can be secreted outside of the cell (2). IL1β binds to the IL-1 receptor (IL1-R) on the outside of cells and induces downstream signaling
cascades that lead to increased expression of transcription factors that aid in the recruitment of
immune effector cells into the extravascular space and activate lymphocytes and epithelial
cells (80). IL-1β also induces IL-2 and TNFα through the activation of T-helper cells, and
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produces tissue inflammatory actions by activating cyclooxygenase-2 to produce prostaglandin
E2, inducible intercellular adhesion molecules and NO (81). Once mature, IL-18 induces the
secretion of IFN-γ by many cell types , which activate macrophages and natural killer cells and
recruit neutrophils to the site (82).
Although the end products of inflammasome activation are known, it is still unclear the
exact mechanism(s) that regulate the second step and the inflammasome as a whole. Researchers
have suggested reactive oxygen species (ROS), changes in cell volume from sodium overload,
potassium efflux, calcium signaling and lysosomal disruptions as the critical upstream signals
required for its activation (83-91). Three different proposed models of the second activation
signal are as listed 1. Efflux of K+ through pores made during the binding of ATP to the
purinergic P2X receptors, which are ion channels that allow potassium to flow through and open
within milliseconds of binding to ATP 2. Phagocytosed environmental irritants cause lysosomes
to rupture, inducing activation. PAMPs, DAMPs and endogenous crystals can trigger the
generation of ROS, which then promotes activation of the inflammasome. 3. Extracellular
calcium influx results in the activation of the inflammasome (92). However, it is still being
researched which proposed model is correct, especially as multiple models may interact with one
another to act as a second signal together.
Moreover, experimental evidence strongly suggest a link between the NLRP3
inflammasome and MS. Examples include, plaques and peripheral blood mononuclear cells from
patients with MS that show elevated mature caspase-l (93, 94). Along with high levels of IL-18
in the peripheral blood mononuclear cells in MS patients when compared to non-MS controls
(95). Much research has found there to be a link between the severity of MS and the levels of the
cytokine interleukin IL-1β and its receptor (96-100). In fact, the progression and susceptibility of
13

relapse-onset in MS patients appears to be interrelated with increases of IL-1β (100-102) and
extracellular ATP in CSF samples (103).
As previously mentioned, the NLRP3 inflammasome is necessary for proper EAE
development. NLRP3 (Nlrp3−/−) knock out mice do not develop EAE or have significantly
reduced severity of disease, with less IFN- γ and Th1 and Th17 helper T cells (104, 105).
Furthermore, mice deficient in caspase-1 are also resistant to developing EAE (94, 106) and
apoptosis-associated speck-like protein (ASC−/−) knock out mice show similar resistance as
(Nlrp3−/−) mice do in EAE severity (107, 108). These results suggest a critical role for NLRP3
inflammasome in EAE pathogenicity and progression.

Fig. 1
Fig. 1- Inflammasome complex: Signal 1, binding of PAMPS or DAMPS to TLRs on outside of innate immune
cells. Signal 2, mechanism not completely known, possible combinations of ROS, calcium influx, potassium efflux,
lysosomal damage or ATP.

1.5. Possible Inhibitors of NLRP3 inflammasome
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It would seem logical that inhibiting the end products of the inflammasome, IL-18 and
IL-1β would be beneficial, and in fact, many therapeutic strategies do just this. Inhibition can be
seen in the IL-1β antibody called canakinumab and the IL-1 receptor antagonist, anakinra, both
of which have been used in multiple MS drug trials and even for the FDA approved treatment for
Rheumatoid arthritis (109, 110). However, safety concerns may arise since there could be
consequences of complete IL-1β inhibition due to the multifactorial roles of the cytokine in the
immune defense against pathogens. There are also strategies for blocking the IL-18 with
numerous clinical trials underway to use the antibody GSK1070806 against IL-18. This molecule
has been previously used to treat B-cell non-Hodgkin’s lymphoma and inflammatory bowel
disease (111). Moreover, some clinical trials are underway to try and target specific constituents
of the inflammasome pathway rather than the end products after they have already been secreted.
Common targets include blocking NF-κB, ATPs ability to bind to P2X and cause K+ efflux,
caspase-1 cleavage, ASC and Ca2+ influx (112). In the case of calcium, research has shown that
when Ca2+ mobilization from the endoplasmic reticulum is blocked, the assembly and activation
of the inflammasome is inhibited (83) and Ca2+ accumulation is implicated in the pathology of
autoimmune CNS inflammation due to the activation of proteolytic enzymes which produce ROS
and cause mitochondrial damages and bio-energetic failures (113, 114). Furthermore, studies in
mice and rats suggest that calcium influx through voltage gated channels, contributes to white
matter damage in neurodegenerative disorders (115). Because calcium increases have been
shown to play a role in MS by boosting axonal injury (113) and blocking Ca2+ mobilization
hinders the inflammasome, calcium blockers may be a good potential avenue for MS
therapeutics. Other studies have shown that increases in cytosolic Ca2+ do not affect caspase-1
dependent processing of pro-IL-1β but can increase the release of processed mature IL-1β in-
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vitro (116). Oligodendrocytes are also sensitive to activation of calcium and its increase as been
shown to mediate demyelination and toxicity (114). Therefore, dysfunction in calcium signaling
in neurons is becoming an ever-increasing avenue for new treatment strategies in autoimmune
disorders and MS. Thus, in researching ways to hinder MS disease progression our lab has been
focused on the organic compound farnesol.
1.6. Farnesol
Farnesol (FOL) is a 15-carbon acyclic sesquiterpene isoprenol that is made through the
Mevalonate (MVA) pathway and is derived from the dephosphorylation of farnesyl diphosphate,
a key intermediate in the cholesterol synthesis pathway in all plants and animals (117). The
MVA pathway is also responsible for the production of vitamin K, coenzyme Q-10 and all
steroid hormones (118). Terpenoids, including carotenoids, isoprenoids and alcohol isoprenols
such as FOL can be used for both herbal and dietary uses (119, 120). Dietary sources that
contain farnesol are many fruits such as plums, blueberries, apricots, raspberries, peaches
tomatoes and strawberries and herbs like lemon grass and chamomile (121, 122), and the
essential oils of citronella and ambrette seeds (123). In addition, previous research conducted by
one of our own collaborators, Dr. Jean-Baptiste Roullet at WSU College of Pharmacy and
Pharmaceutical Sciences, has shown farnesol to be an antagonist of both L and N-type voltage
gated Ca2+ channels (124, 125). Farnesol provides protective effects against oxidative stress, and
to have anti-inflammatory effects in vitro (126). Farnesol also reduces the levels of iNOS, and
the pro inflammatory cytokines TNF-a and IL-1β (127, 128). Neuroprotective properties
of FOL have also been documented in an LPS-induced murine model of neurodegeneration
and in a model of acrylamide-induced neurotoxicity, through the regulation of the production of
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free radicals and pro-inflammatory cytokines. Moreover, FOL treatment improved the
neuromuscular function, fine motor coordination and the gait in mice of these models (129).

Currently there are 18 FDA-approved disease modifying treatments on the market to treat
MS, most of which focus on the adaptive immune system rather than the innate. However, these
medications show inadequate effectiveness, do not target all symptoms and may result in a broad
spectrum of negative side effects in patients (130-132). They either target inflammation or
neurodegeneration but none target them simultaneously. Whereas farnesol has been shown to
target them both concurrently and therefore could be a potential novel therapeutic for MS.

In addition, FOL is also known as a quorum-sensing molecule and can impact microbial
life by regulating the formation and detachment of biofilms. Biofilms are extracellular structures
produced by microbes that secrete extrapolymeric matrix substance (EPS). These structures form
a complex and protective microbial communication system produced in conditions of ample
nutrients and efficient against environmental insults such as UV light, desiccation, changes in
temperature or pH. Biofilms are also effective against microbial predators, antibiotics, and the
host’s immune system, constituting an important clinical challenge when combating infections
(133). Farnesol has been shown to inhibit the formation of biofilms made by fungal strains of
Candida albicans (134, 135) and the gram-positive human pathogenic strain methicillin-resistant
Staphylococcus aureus (MRSA) (136, 137). Interestingly, studies in other bacterial strains, such
as Bacillus subtilis, reported that farnesol can actually promote biofilm formation (138). Because
of these opposite effects and the importance of biofilms in the overall structuration of the
intestinal ecosystem, oral farnesol may affect the composition of the gut microbiota in EAE
induced mice.
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Since autoimmune inflammation, oxidative stress, calcium overload, neurodegeneration
and possible gut dysbiosis are symptoms that are associated with multiple sclerosis, my thesis
will explore farnesol and its potential therapeutic ability to reduce the severity of disease and
provide protection against the murine model of experimental autoimmune encephalomyelitis.

2. Hypotheses
Because of the documented neuroprotective effects of farnesol, and the impact of farnesol
on biofilm formation, a biological multispecies structure observed in the intestinal microbiota,
that in turn, is susceptible to changes during MS, I hypothesize that: 1) The oral treatment with
farnesol provides protection and reduces the onset and severity of EAE in mice; 2) Farnesol is
changing the composition of the intestinal microbiota of EAE mice.
3. Materials and Methods
3.1. Animal safety and well-being
C57BL6 mice (Envigo and Harlan) were housed at the vivarium in Eastern Washington
University, Cheney. Mice will be housed in cages with other mice (no more than 5 per cage) to
provide them with social interaction. All mice will be housed in a standard EWU animal facility
cages with wire top, at temperatures of 22 +/-1°C, a humidity of 23-33 %. The dimensions of
cage are 46 cm x 25cm x 20 cm, and the mice will live with a 12-hour light and 12-hour dark
cycle. Food and water will be administered ad libitum during the experimental period. Each
mouse will be fed 4g of Teklad pellet food per day, as recommended by the Human Society of
the United States. All animals are treated and cared for in accordance to the policies established
by the approved IACUC protocol and institutional policies for animal health and well-being.
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3.2. EAE induction
Active EAE was induced using the Hooke Kit™ (Hooke Laboratories, EK-2110) which
contains the self-peptide MOG35-55, naturally present in myelin, emulsified in complete Freund’s
adjuvant (CFA). Each animal was given two subcutaneous injections of the self-peptide,
emulsified in CFA on day 0. After MOG35-55 injection, mice received varying amounts (as listed)
of Bordetella pertussis toxin (PTX) in glycerol buffer depending upon the experiment,
intraperitoneally (List Biological Laboratories, Campbell, CA; provided with Hooke Kit™ for
EAE Induction) on day 0 and on day 1. Using EAE kit scoring guidelines, mice were monitored
and scored daily for disease progression and frequent observations were made of each mouse’s
health and well-being, including weights and collection of stools for potential gut microbiota
analysis.
EAE clinical scores were evaluated as follows. Mice were scored as described by us and
others: 0 – no detectable signs of EAE, 0.5 – distal limp tail, 1.0 – complete limp tail, 1.5 – limp
tail and hind limb weakness, 2.0 – unilateral partial hind limb paralysis, 2.5 – bilateral partial
hind limb paralysis, 3.0 – complete bilateral hind limb paralysis, 3.5 - complete bilateral hind
limb paralysis and partial front limb paralysis, 4.0 - quadriplegia. To ease access to water, mice
were given water bottles upon the day of disease induction. To ease access to food, when mice
exhibited a score of 2.5, food was soaked with water and left in a shallow cup placed close to
where mouse bedding was located.
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3.3. Microbiota Analysis
Samples were sent to AKESOgen (Norcross, GA) for 16S rRNA analysis of the
microbiota. Qiagen DNA stool extraction kits were used for DNA isolation. DNA aliquots (1
ng/ml DNA) were analyzed by PCR using primers specific to the variable region 4 (V4) of
prokaryotic 16S rRNA gene. Library preparation and sequencing for V4 amplicon sequencing
was performed on the Illumina MiSeq platform. A modified protocol with Nextera XT kit was
used for library preparation, and sequencing was performed using MiSeq V2(2x250bp)
chemistry. AKESOgen used a protocol that combined the 2-steps in 1-step of amplification with
forward and indexed-reverse primers. Once the sequencing was performed, we used a cloudbased web application for analyzing microbiota data from the Office of Cyber Infrastructure and
Computational Biology (OCICB), National Institute of Allergy and Infectious Diseases.
3.4. Experimental Outlines
Experiment 1.
9-week-old female C57BL/6 mice (Harlan Labs) were put into 2 groups. Group 1: No
treatment, control mice induced with EAE (n=10). Group 2: Mice induced with EAE and given a
daily oral gavage of farnesol 100 mg/kg body weight solubilized in a vehicle of corn oil
(n=10). Those induced with EAE were given 250 µg myelin oligodendrocyte peptide 35-55
(MOG35-55) emulsified in 250 l of complete Freund’s Adjuvant (CFA) and 125 ng pertussis
toxin (PTX) intraperitoneally on day zero. On day 1 mice were given another intraperitoneal
injection of 125 ng of PTX. Daily EAE clinical scores were recorded, along with weekly weights
(g) and percentage of weight gain/loss was compared with initial weight. While these results
showed promise for the potential protective effects of farnesol, there are issues with the
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experiment, as it is lacking in a proper control and does not show what affects the vehicle of corn
oil, may have on disease severity and onset. Thus, the next experiment was conducted with a
control of corn oil.
Experiment 2.
10-week-old C57BL/6 female mice (Envigo) were put into two groups of mice. Group 1:
Treatment group; mice inoculated with EAE and given a daily oral gavage of 100 mg/kg body
weight of farnesol solubilized in corn oil, starting at day 0 (n=5). Group 2: Mice inoculated with
EAE and given a daily oral gavage of 100 µl of corn oil, starting at day 0 (EAE induction),
(n=5). EAE Induced mice were given 250 µg myelin oligodendrocyte peptide 35-55 (MOG35-55)
emulsified in 250 l of complete Freund’s Adjuvant (CFA) and 130 ng pertussis toxin (PTX)
intraperitoneally on day 0. On day 1 mice were given another intraperitoneal injection of 130 ng
of PTX. Daily EAE clinical scores were recorded, along with weekly weights (g) and percentage
of weight gain/loss was compared with initial weight. On day 20, all mice were euthanized using
CO2 followed by cervical dislocation.
Experiment 3.
Next, experiment was repeated in order to confirm the results seen in previous
experiment, with added microbiota analysis. EAE was induced in C57BL/6 mice (Envigo) on
day 0 and scores were evaluated daily. Group 1: EAE no treatment (n=12). Group 2: EAE and
oral gavage of corn oil 100 µl (n=12). Group 3: EAE, oral gavage of farnesol 100mg/kg body
weight solubilized in vehicle of corn oil (n=8). Those induced with EAE were given 250 µg
myelin oligodendrocyte peptide 35-55 (MOG35-55) emulsified in 250 l of complete Freund’s
Adjuvant (CFA) and 150 ng pertussis toxin (PTX) intraperitoneally on day 0. On day 1 mice
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were given another intraperitoneal injection of 150 ng of PTX. Daily EAE clinical scores were
recorded, along with weekly weights (g) and percentage of weight gain/loss was compared with
initial weight. On day 26 only EAE survivors were compared. Due to the effects described for
farnesol on the formation and detachment of biofilms we sought to compare the impact of
farnesol treatment on the intestinal microbiota, a complex ecosystem where biofilm is present.
Stool samples were collected in sterile tubes on days 0, 14, and 26 and stored at -80°C
4. Statistical Analysis
Mixed-effect analysis of the variance was used to calculate the statistical significance of EAE
clinical scores, cumulative scores, body weights and % body weights vs. initial weights. The
disease onset and severity index among groups were compared by non-parametric KruskalWallis followed by Dunn’s multiple comparisons tests.
For the analysis of the microbiota, R was used. The composition of the different
microbiota determined by PCoA analysis and compared by ADONIS (adjusted p values
provided), while alpha diversity and Firmicutes:Bacteroidetes (F/B) ratios were compared by
non-parametric Kruskal-Wallis followed by Dunn’s multiple comparisons tests. The analysis was
performed with Prism (version 8.1.1), from GraphPad Software, Inc. QIIME was used for
analysis (139) and R for statistical analysis (140). The Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States (PICRUSt) package was also used with
Nephele-microbiome analysis. A total of 83 samples were compared using the QIIME FASTQ
paired end protocol. Reads that were demultiplexed were clustered into OTUs open reference
approach by comparison with the SILVA_99 database allowing sequences clustered at 99%
similarity. Analysis included the identification of chimeras and removal using uchime. The
abundance of each taxa was analyzed using the phyloseq package in R (140). We visualized the
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compositional heterogeneity of the microbial community of each sample at every time point and
at each taxonomic level using PCoA scaling using the ordinate function in the phyloseq package,
and the metaMDS function in the vegan package, using the Bray-Curtis dissimilarity index.
5. Results
FOL Treatment Improves EAE Outcome Compared to Untreated Mice. (Exp 1.)

Fig. 2

Fig. 3

Fig. 4
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Fig. 5

Results show that there was a significant amount of protection in EAE induced mice that
were given farnesol when compared to mice that did not receive farnesol (*, p<0.01) (Fig. 2).
The cumulative scores per group were also statistically significant with farnesol scores per
group=80 and untreated control scores per group =365. (**, p<0.001) (Fig. 3). However, the
daily onset for disease symptoms were equal in both groups, with symptoms on average both
starting on day 9.4 (Fig 4.). The severity index shows that untreated control group has higher
scores than then farnesol treated group (***,p<0.0001) (Fig. 5). However, as previously
mentioned, this experiment lacked a proper control of corn oil.
Corn Oil Affects the Protection Induced by FOL. (Exp 2.)

Fig. 6
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Fig. 7

Fig. 8

Fig. 9

Therefore, to control for any possible effects that corn oil may have on EAE progression, in
this experiment control EAE mice were given a daily oral gavage of corn oil. The results of
experiment 2 show that mice given farnesol had a statistically significant reduction of disease
onset of EAE and took 14 days to show symptoms, whereas control mice took only 8.8 days
(**,p<0.001) (Fig. 7). The severity index, which is the individual cumulative scores/number of
days with symptoms (a score above 0), was not statistically significant with farnesol having an
average severity index of .75 and the control average was .88 (Fig. 8). Also, when assessing the
cumulative scores per group there was no statistical significance either (Fig. 9).
This experiment continues to show farnesol’s protective ability to reduce disease severity and
onset in EAE induced mice. However, to further quantify the extent of farnesol’s protection
future experiments should include more mice per group.
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FOL Treatment Does not Affect Overall Composition of Intestinal Microbiota but Modifies
Firmicutes/Bacteroidetes ratio. (Exp. 3.)

Fig. 10

Fig. 11

Fig. 12

Fig. 13

Oral treatment with farnesol reduced significantly the average scores in mice when compared
with untreated EAE mice (*, p < 0.05; **, p < 0.01; ***, p < 0.001). The daily treatment with
corn oil (vehicle) also reduced the scores in mice when compared to untreated EAE mice (#, p <
0.05; ##, p < 0.01), although the significance was lost on day 26. At the end of the experiment
(day 23 – 26) the scores in FOL-treated mice were significantly lower than in vehicle-treated

26

mice (τ, p < 0.005) (Fig. 10). The statistical analysis was performed by mixed-effect analysis
followed by Tukey’s multiple comparisons test. EAE onset was delayed in vehicle- (#, p < 0.05 )
and FOL-treated mice (**, p < 0.01) when compared with untreated mice (Fig. 11).The severity
index of untreated EAE mice was significantly higher than in FOL-treated mice (***, p < 0.001)
(Fig. 12). Cumulative scores between groups show a statistical significance when comparing the
untreated EAE mice vs the farnesol treated EAE mice (***, p < 0.001) (Fig. 13).

Fig. 14

Fig. 15
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Figure 10 A and B. Alpha diversity quantified by Shannon index (A) and Chao1 index (B). The results of the analysis are
depicted as mean +/- minimum and maximum and compared by Kruskal-Wallis analysis followed by Dunn’s multiple
comparisons test (*, p < 0.05; ***, p < 0.001).

There were no significant differences between experimental groups in the Shannon and
Chao1 indices at day 0. By day 14 we observed a significant reduction in the Shannon index of
EAE animals treated with farnesol when compared with untreated mice (p < 0.001) and with
vehicle (p < 0.05). Chao1 index was significantly reduced in farnesol-treated EAE mice when
compared with vehicle-treated EAE (p < 0.05), although no differences were observed between
farnesol-treated and untreated EAE mice. At day 26, vehicle-treated mice showed an increased
Shannon index when compared to untreated EAE mice while no differences were detected
between untreated and farnesol-treated EAE mice, or between vehicle-treated versus farnesoltreated EAE mice. At this timepoint the analysis of Chao1 alpha diversity measurement did not
show any significant differences among groups (Fig. 10 B).

Fig. 16
Figure 11. Impact of EAE induction and treatment on the composition of the intestinal microbiota. PCoA analysis for the genus
taxonomic level of OTUs identified in samples obtained from untreated EAE mice (EAE), vehicle-treated EAE mice (VEH), and
FOL-treated EAE mice (FOL) at days 14 (A) and 26 (B). The results of the analysis were compared by ADONIS.
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When compared by ADONIS, the analysis showed that disease progression affected the
overall pool of putative functional pathways. At disease onset (day 14), the analysis revealed
statistical differences between farnesol-treated mice and mice in the other experimental groups.
At day 26 however, only vehicle-treated EAE mice showed significant differences in the overall
functional analysis when compared with both untreated and farnesol-treated EAE mice.

Fig. 17
Figure 12 shows the impact of EAE induction and treatment on the composition of the intestinal microbiota.
Firmicutes/Bacteroidetes ratio quantified in stool samples. The results of the analysis are depicted as mean +/- SEM and
compared by Kruskal-Wallis analysis followed by Dunn’s multiple comparisons test (*, p < 0.05; **, p < 0.01).

Although the specific effects of farnesol on EAE mouse intestinal biofilms needs to be
evaluated further, we observed that farnesol treatment affected the overall composition of the
microbiota and specifically the F/B ratio. There was no significant difference among groups at
days 0 and 14, but at day 26, the F/B ratios of the farnesol-treated mice were on average
significantly lower than those of the untreated (p < 0.01) and vehicle-treated (p < 0.05) mice (p <
0.05). (Fig. 12). Our results suggest that, although no specific microbes were identified as
differential source based on adjusted p value analysis, the treatment with farnesol changes the
composition of the microbiota, particularly when comparing Firmicutes and Bacteroidetes. The
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respective pathogenic or protective roles of Firmicutes and Bacteroides in diseases is uncertain.
However, a number of studies have reported lower levels of Bacteroides (hence higher F/B ratio)
in inflammatory disease of the gut (141-144). It is thus tempting to propose that the
neuroprotective effect of farnesol is mediated in part by a change in the composition of the gut
microbiota, and subsequent attenuation of the autoimmune response, thus providing indirect
support to a gut-brain axis participation in MS pathogenesis.
6. Discussion
This data demonstrates that farnesol is providing protective effects in the mouse model of
multiple sclerosis, experimental autoimmune encephalomyelitis. Displaying that daily oral
treatment with 100 mg/kg body weight of farnesol significantly reduces the clinical severity of
the disease. The data also shows that oral farnesol administration significantly modifies the
composition of the intestinal microbiota and suggest that the improvement of gut dysbiosis (more
Bacteroides, less Firmicutes) could be a novel avenue for MS therapeutics. Although
preliminary, these findings provide evidence that farnesol reshapes the imbalanced microbiota of
EAE mice and raises the possibility of a beneficial impact of farnesol on the gut-brain axis as a
mediator of its clinical activity.
A potential constraint of these studies is the confounding yet beneficial activity of the vehicle
corn oil which is used for administering the farnesol. One recent work has reported that the oral
administration of extra-virgin olive oil induced protection against EAE using a rat model (145).
This protection is believed to be attributed to the high proportion of omega-3 fatty acids in extravirgin olive oil, which has been described as having anti-inflammatory effects (146). In contrast
corn oil contains higher amounts of omega-6 fatty acids which is associated with proinflammatory effects (147). However, using LC-MS/MS, we found that that farnesol can be
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detected in olive oil but not in corn oil (data not shown), hence the choice of corn oil as vehicle.
These findings that corn oil provides significant neuroprotection in EAE mice (Fig. 8.A)
confirms previously published studies in which corn oil was used as vehicle (148) and highlights
the importance of using clinically-neutral vehicles in studies testing novel therapeutics in
experimental MS, particularly in studies that focus on the microbiota. It is important to note here
that the combination of farnesol and corn oil provides superior clinical benefits compared to corn
oil alone, raising the possibility that additive or synergistic mechanisms of action are at play.
Here future studies will be needed to delineate the respective contribution of vehicle and farnesol
to neuroprotection.
In addition, our lab did additional EAE experiments using farnesol. An overview of the data
shows p-values of EAE/untreated mice vs EAE/farnesol mice and EAE/vehicle of corn oil vs
EAE/farnesol are both <0.0001. The severity index of EAE/untreated vs EAE/farnesol had pvalue of <0.004, EAE/vehicle of corn oil vs EAE/farnesol had a p-value of <0.01. Furthermore,
these experiments include studies covering T-cell infiltration into brains and spinal cords of the
CNS of FOL treated EAE mice. These experiments will be covered in more detail by my lab
mate Christina Ramelow in her thesis, but the results continue to show the benefits of FOL in
EAE mice. However, even though these experiments have continued to highlight the potential of
FOL as a therapeutic, it is unclear what mechanisms farnesol is using to provide these protective
effects.
7. Future Directions
Due to the current pandemic and the restraints it has imposed, further investigation into
what mechanisms farnesol is potentially using to provide protection against EAE were not able
to be completed at this time. Thus, I will outline my previously intended hypotheses,
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methodology for testing them and what results I would have expected had I been able to finish
these experiments.
With the knowledge of farnesol’s properties and the probable mechanisms of MS pathology,
I hypothesized that farnesol may be protective against EAE by inhibiting the activation of the
inflammasome. MS pathologies are believed to include oxidative stress, autoimmune
inflammation and intraneuronal Ca2+ overload and farnesol is an inhibitor of Ca2+ channels (124,
125) and is known to reduces oxidative stress (149), both of which are believed to be activators
of the inflammasome complex. Therefore, by reducing Ca2+ and ROS, the inflammasome
complex is inhibited from being activated, lessening inflammation and leading to reduction in
EAE disease severity. Several experiments would have been done in order to check this
hypothesis.
Methods
Firstly, bone marrow derived macrophages would be isolated and cultured from C57BL/6
mice. After CO2 euthanasia the femurs and tibias of mice will be surgically removed, and the
skin and muscles will be cleaned off. Next, an 18-gauge needle will be pushed through the
bottom of a microcentrifuge tube and long bones will be placed in, knee end down. This tube
will be placed in a 1.5 ml tube and centrifuged (10,000 x g for 15 seconds). Red blood cell lysis
buffer will be added to tube (0.25 ml for 3 mins.) and then will be centrifuged (300 x g for 5
mins.) and the supernatant discarded, and pellet washed with PBS. Cells will be resuspended in
(10 ml) RPMI (1640) medium with 10% heat inactivated fetal bovine serum (FBS). Cells will be
plated into tissue culture treated suspension plates (10 cm) and incubated at 37 C° and 5% CO2
overnight to allow for cells to adhere to plate (150). The next day cells will be collected and
moved to non-culture tissue treated suspension plates (60mm) with 2 ml of RMPI media and 20
32

ng/ml of macrophage colony-stimulating factor (M-CSF) to allow for macrophage
differentiation. Every two to three days cells will have media aspirated off and washed with PBS
and fresh RPMI media and M-CSF added. On day 5 cells can be harvested for further
experiments, using Accutase solution to remove them from the culture dishes.
Cell treatments
Next, collected cells will be counted using a hemocytometer and will be plated into a 12
well plate at ~500,000-700,000 cells per well and RPMI without FBS will be added (2 ml per
well). Media must not contain FBS at this step, since it is known to alter levels of the proinflammatory cytokine IL-1β, that is released by the inflammasome (151), and the serum also
overloads the concentrated samples used for western blots (152).

Fig. 18

The plated cells will then be subject to treatments to access farnesol’s effect on the
inflammasome. Of the 12 wells three will be control with no treatment, three will be given LPS
and ATP, three will have LPS, ATP plus 10 mM FOL and the last three wells will have LPS,
ATP and 25 mM FOL. The wells that have LPS will receive ultra-pure LPS (InvivoGen) at 100
ng/ml and the plate will be incubated at 37 C° and 5% CO2 for 3 hours to allow for the
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stimulation of the first signal of the inflammasome pathway. After 3-4 hours cells will then be
aspirated and washed with RMPI. Next, treatment macrophages will be given FOL at either
10mM or 25 mM concentrations to see if varying concentrations will affect the activation of the
inflammasome in any way. This solution of FOL will be (977 l of farnesol added to 2 ml
DMSO for stock solution: Then 25 l per well for 25 mM or 10 l for 10 mM) and will treat
cells for 30 minutes. Without washing off the farnesol cells will then be given a solution of ATP
(5 mM) to stimulate the second step of inflammasome activation. The ATP and FOL will treat
the cells for 30 minutes in the incubator at 37 C° and 5% CO2. After 30 minutes use ice cold
RIPA lysis buffer (Thermo Fisher 87787) with protease and phosphatase inhibitors (ab201119) is
added (50-70 l per well) to detach cells. Transfer cells to eppendorf tube, sonicate for 15
seconds on full power and centrifuge (10,000 x g for 5 min.) saving the supernatant. Next, a
bicinchoninic acid assay (BCA) (Pierce 23228) will be done to quantify the total protein per
well. BCA results should be above 100ng/ml. Protein concentration will be adjusted to 1.5 ug/ul
using lysis buffer to dilute. Cell lysates will then be subjected to SDS-PAGE and transferred to a
polyvinylidene fluoride membrane for Western blot analysis of inflammasome components.
Western blot analysis
Western blot analysis will be performed using antibodies for NLRP3, IL-1β, IL-18, procaspase-1, caspase-1 and ASC of the inflammasome complex. Cell lysates will be mixed with
loading buffer and boiled at 95°C for 5 minutes. Microtubes will be spun down for a few seconds
in a bench minicentrifuge. Equal amounts of protein (20-30 g of total protein) will be loaded
into the wells of the SDS-page gel, along with molecular weight markers. The gel will be ran at
60 V until protein enters the stacking gel and then at 120 V for 1 to 1.5 hours. Then the protein
from the gel will be transferred onto a Polyvinylidene difluoride (PVDF) membrane that is
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soaked in transfer buffer for 15 minutes before transfer. The membrane will be blocked with 5%
bovine serum albumin (BSA) for 2 hours at room temperature. Membrane will be incubated with
primary antibodies overnight at 4°C. Membrane will be washed with BSA x 3. Membrane will be
incubated with secondary antibodies in 5% BSA for 1 hour at room temperature. Membrane will
be washed with BSA x 3. A chemiluminescence substrate will be added to the membrane for 5
minutes at room temperature (153). Excess substrate will be removed, and chemiluminescent
images of Western blots will be developed and saved to assess the effects of FOL on the
components and products of the inflammasome.
Cytosolic [Ca2+] detection
The same parameters and cell treatments previously outlined will be used to study how
FOL potentially changes the levels of calcium and how that effects the activation of the
inflammasome. The levels of intracellular calcium will be detected using Fura-2 AM assay
(Avantor 108964-32-5). In a separate plate the LPS, ATP and FOL treatments will be
administers as described above. Cells will be detached using Accutase and resuspend in RPMI
and centrifuge (300 x g, 5 mins). The cell pellet will be collected and resuspended in 0.5 ml
Hanks balanced salt solution (HBSS) with 1 mM CaCl2 and Fura-2 AM. After incubation at
37°C with 5% CO2 for 45 min, wells will be washed with HBSS with CaCl2 for 3x. Calcium
concentrations will be measured using a spectrofluorometer. Baseline fluorescence (485 nm
excitation → 528 nm emission at 30-s intervals) will be recorded for 10 min. The Fmax and Fmin
values will be used to calculate the cytosolic [Ca2+] corresponding to changes in 485ex→528em
fluorescence of Fura-2 within the intact cells (154).
Intracellular ROS detection using Flow cytometry
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Next, to access if FOL is changing the levels of ROS and thereby inhibiting
inflammasome activation intracellular ROS will be detected using CellROX Green kit
(Invitrogen). In a separate plate the LPS, ATP and FOL treatments will again be administers as
described above. The CellROX reagent will be added to cells at a final concentration of 500 nM
and incubated for 30-60 minutes at 37°C and 5% CO2, away from direct light, (1 l of CellROX
reagent with 9 ul of DMSO to make 250 uM solution: use 2 ul of solution to stain 1 ml of cell
suspension, at a final concentration 500 nM). During final 15 minutes of staining, 1 l of 5 M
SYTOX Red Dead Cell stain solution in DMSO will be added for every 1 ml, at a final
concentration of 5 nM and mixed gently. Samples will then be analyzed using flow cytometry at
488-nm excitation for CellROX green and 639-nm for SYTOX red stain to look for levels of
intracellular ROS (155).
Expected results
If FOL is inhibiting the inflammasome complex by either blocking an influx of Ca2+ or
reactive oxygen species, as hypothesized, these would be the expected results. Western blots
would show that the LPS/ATP treated groups would have pro-caspase-1, caspase-1, IL-1β, IL18, NLRP3 and ASC would be increased when compared to the control of no treatment.
However, all should be decreased in the LPS, ATP and FOL treated wells when compared to the
LPS, ATP wells and the control wells. When considering data from the above-mentioned
experiments, it would seem likely that the decrease in the selected antibodies would be in a dose
dependent manner based on how much farnesol the cells are being treated with. Those being
treated with the 25 mM FOL would show more reduction in pro-caspase-1, caspase-1, IL-1β, IL18, NLRP3 and ASC than the cells treated with only the 10 mM of FOL would.
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With regards to the intracellular Ca2+ assay, these would be the expected results. Since
FOL is a blocker of voltage-gated calcium channels, the levels of intracellular Ca2+ would be less
in those that are treated with FOL when compared to either the control or the LPS and ATP
treated cells. Again, a dose dependent manner of farnesol would seem likely in this scenario as
well, with the 25 mM FOL treated cells showing less intracellular Ca2+ than the 10mM treated
cells do.
Farnesol is known to inhibit reactive oxygen species and therefore results would be
expected to show a reduction in ROS within cells that are treated with FOL when compared to
cells in the control or in the LPS and ATP group. A dose depended manner would also be
probable with those receiving 25 mM of FOL having less ROS than those receiving only 10 mM.
It is true that the molecular and cellular mechanisms of action underlying the
neuroprotective activity of FOL in experimental MS have yet to be elucidated at this time.
However, if the results were as formerly described it would imply that FOL is able to inhibit the
inflammasome by either blocking Ca2+ influxes, ROS or both and consequently hinders the
assembly and the activation of the inflammasome, stopping the release of the pro-inflammatory
cytokines IL-1β and IL-18. Without the activation of the inflammasome and release of these
cytokines it would be proposed that the severity and progression of EAE could be altered and
lessened. If this is true, FOL may be an exciting and novel therapeutic for treating MS through
the innate immune pathway instead of the adaptive pathway, as most current treatments on the
market do. Further studies will be needed to fully characterize farnesol’s contribution on each of
these specific pathways within the inflammasome complex and how they may alter the
neuroprotective activity of the isoprenol farnesol within the EAE model, with the goal of helping
to find better therapeutics for the treatment of patients with MS.
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Abstract
The gut microbiome consists of trillions of microbes that reside within the gastrointestinal tract. These
microbes have been shown to collectively aid in immune, endocrine and neural system functions and
development. However, the gut microbiome can be altered in many ways including by infections,
antibiotic use, geography and diet. A disruption in the homeostasis of normal intestinal microbiota,
known as dysbiosis, can results in changes believed to lead to pathological pathways which may mediate
the development and progression of autoimmune diseases such as Multiple Sclerosis. When compared
to healthy individuals, clinical evidence shows those with autoimmune diseases have distinct microbiota,
and those with MS have altered concentrations of specific microbial taxa. Furthermore, the risk for MS is
two-times greater in individuals who are obese during adolescence and the rate of MS is highest when
body mass index (BMI) is >27. Therefore, dietary interventions as a possible therapeutic to modulate the
composition of the microbiome and thus reduce the incidence or severity of disease are a crucial next
step and could be a breakthrough in the treatment of MS. Further studies are needed to assess the
exact mechanism by which the gut microbiota and diet are impacting disease occurrence and
progression.
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X.1

Multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). The

neurological manifestations of MS have been attributed to exacerbated immune response and
inflammation in the brain and spinal cord. In MS CNS factors yet to be elucidated, attack the myelin sheath
that protects neuronal axons causing demyelination, loss of axons and loss of the oligodendrocytes ability
to remyelinate and eventually neuronal death.1 This neuronal damage is a direct result of immune cells
inability to discern between self and non-self, causing an autoimmune reaction. The axonal demyelination
in white and grey matter of the CNS causes a plethora of symptoms that include initial manifestations
such as muscle weakness, loss of coordination, numbness, and , double or blurring vision and at later
stages can advance into severe paralysis, pain, mood disorders, depression and disturbances in urinary,
sexual and gastrointestinal functions among others.2 MS is a complex disease that is initiated by a clinically
isolated syndrome (CIS) and followed by a pattern that can be differentiated into relapsing-remitting MS
(RRMS), primary progressive MS (PPMS) or secondary progressive MS (SPMS).3 Approximately 80% of
RRMS patients develop SPMS. In addition, it is considered that a portion of MS patients develop a mild
form of MS defined as benign MS although the clinical existence of this less severe form is still under some
debate.4
MS has a prevalence of 50 to 300 per 100,000 individuals, and between 2 to 3 million suffer from MS
worldwide.5 This wide range in prevalence is due to geographical location. With only a few exceptions,
the prevalence of MS is shown to be higher in countries in the northern hemisphere and that rates
increase with increasing latitude. Although the exact cause of this trend is still unknown, it provides
evidence that there may be a link between geography and being at risk of developing MS.5 The female to
male ratio, similar to other autoimmune diseases, is close to 3:1.6 As it occurs with other human diseases,
polymorphisms in the Human Leukocyte Antigen (HLA) region of genes in the chromosome 6 have been
linked to an increased risk for the development of MS. Genome-Wide Association Studies (GWAS) suggest
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HLA regions but also suggest other immune system genes such as interleukin 2 receptor alpha (IL2RA) and
interleukin 17 receptor alpha (IL17RA) among others which are known to be associated with MS.7 Although
major advances have occurred in recent decades, the causative factor that triggers MS is still unknown.
However, it has been posed that a combination of genetic susceptibilities8 and environmental risk factors
is a major contributor for MS induction and perhaps progression.9
Multiple environmental risk factors have been proposed for MS, such as smoking, previous viral
infections, vitamin D deficiency, and others, including adolescent obesity.9 Because of the numerous
factors that must be considered and because comorbidities are common in MS, it is plausible that multiple
different environmental factors merge together in the context of MS etiology.
As we will discuss in the next section, many of the environmental factors that have been proposed to
increase the risk of MS also have the capacity to affect the composition of the gut microbiome.10 Globally,
all microbes of a given system are termed microbiota, while the combination of the microbiota within the
host’s factors is termed the microbiome. Among all of the environmental causes that possibly affect the
composition of the gut microbiome, diet is perhaps the most relevant. With rising levels of childhood
obesity coupled with the fact that higher body mass index (BMI) is a risk factor for developing MS, diet
appears to play a crucial role.11-13 Therefore, next we will explore the link between the diet, the
microbiome and MS in this chapter. We will discuss the main mechanisms by which diet has the capacity
to modulate the composition of the microbiome, and the cover current research on how these
modifications may be altering the microbiome in those with MS. Finally, we discuss the most recent
publications that are providing insights on the potential of diet and its effect on the gut microbiome, as a
novel therapeutic approach for MS.

X.2

Autoimmunity, diet and the gut microbiome
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The microbiome in humans consists of hundreds of trillions of microorganisms including bacteria,
archaea, and eukaryotic microbes along with acellular infectious agents like viruses. Different
microbiomes are defined based on the environment where the microbiota lives. In the context of human
disease, the gut microbiome is the most applicable and therefore the most well studied. This is due to the
important roles that have been described for intestinal microbes which regulate immune, endocrine and
neural system development and functions. The microbial colonization of the gut starts during birth14,15,
although pre-birth colonization is also proposed.16-19 Metagenomic studies indicate that the delivery
method impacts the composition of the microbiome14 and some investigators are exploring the link
between these differences with the occurrence of diseases later in life.20 The diversity of the microbiome
increases with age until the infant is two-three years old.21 Early life events such as infections, use of
antibiotics, and nutrition all have profound impacts on this developing microbiome.21 The environment
where infants lives may also impact future development of immune-related diseases, such as asthma.22
The gut microbiome comprise all microbes harbored in the gastrointestinal tract, with the vast
majority of them being located in the large intestine. Physical factors such as nutrient availability, pH,
oxygen content, and mucus thickness shape the composition of the intestinal microbiota both
longitudinally and transversally.23 In addition, host’s factors such as antimicrobial peptides or proteins,
mucosal secreted IgA (sIgA) immunoglobulins can also impact the composition and symbiotic function of
the gut microbiota.24,25
In addition, what part of the world one lives in can also have an impact on microbiome diversity and
studies have been done to compare the composition of the gut microbiome of individuals living in
westernized and non-westernized countries.26-30 The studies suggest that, overall, the composition of the
microbiome of western individuals is less diverse, with fewer species, than in non-western microbiomes,
and that the pattern of the most common phyla shifts. More recently, research has shown that those who
have immigrated from East Asian countries to the U.S lose their native gut bacteria and eventually develop
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a microbiome that is more “westernized” and less diverse. Adding that these effects increase with
duration of US residency and that they are exacerbated by obesity and across generations.31 However,
seasonal variability as well as changes based on different factors such as sex or age still exists among
populations.29 Despite the complexity of the studies there are still numerous cofounding factors that can
modulate the gut microbiome.32 The effects of diet on the microbiome impact the relative abundances of
taxa as evidenced in studies of the composition of the gut microbiome in individuals depending on their
geographical location.33,34 More controlled experimental studies provide evidence that suggests that the
diet can promote changes in the composition of the gut microbiota, even in as little as a few hours.35
The cellular and molecular mechanisms by which dietary factors impact the composition of the
microbiome are largely unknown. As discussed above a westernized diet, generally known to be rich in
saturated fatty acids, processed sugars, red meats or salt can impact the microbiota. Such diets favor the
accumulation of cholesterol which reduces the fluidity of cellular membranes and could result in
cardiovascular diseases and inflammation.36 High sugar content diets can also result in arachidonic acid
production that in turn would exacerbate proinflammatory responses.36 Furthermore, diets that are high
in salt have been described to promote the induction of proinflammatory, IL-17-producing T helper-17
(Th17) cells that could result in autoimmunity, as suggested based on animal models of disease including
MS.37-39 Dietary fibers are known modulators of the gut microbiome.35 The bacterial fermentation of fiber
carbohydrates produces short chain fatty acid (SCFAs) metabolites in the gut. There are three main types
of SCFAs; acetate, propionate and butyrate. SCFAs are strong immunomodulatory microbial metabolites
that impact the induction of regulatory T cells (Tregs)40 and epithelial and blood-brain barrier
permeability.41 Humans use SCFAs as a source for energy, although in a lesser extent when compared to
other mammals, such as closely related primates. SCFAs are ligands of G-protein-coupled receptors
(GPCRs) that are expressed on epithelial cells, adipocytes, and also by immune cells. GPCR43 signals SCFA
produced by colonic microbiota promote the expression of forkhead box P3 (Foxp3), a master regulator
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that polarizes the differentiation of naïve T cells into inducible Tregs (iTregs) in the periphery and natural
Tregs (nTregs) in the thymus. Once iTregs are induced by SCFA derived from gut microbes the cells then
produce anti-inflammatory cytokines such as interleukin-10 (IL-10).42 Studies show that high-fat-diet
induced (HFD) mice that are deficient in GPR43 receptor, renders them obese and diabetic in a process
regulated by the gut microbiota, showing the importance of this pathway.43
The effects of fibers on CNS inflammatory demyelination was recently tested using a transgenic
murine model of spontaneous EAE.44 The main goal of the study performed by Berer et al. was to
determine whether the supplementation of diet with non-fermentable fibers often present in vegetarian
diets would result in changes in the outcome of EAE. The supplementation consisted on a fiber-rich diet
enhanced in cellulose. The results showed first, that the supplementation significantly impacted the
composition of the gut microbiota and the metabolic pathways triggered with an increase in long chain
fatty acids, which in turn resulted in the promotion of Th2-type immune responses that reduced the
extend of the disease, reducing autoimmunity. Th2-immune responses were characterized by IL-4 and IL5-producing CD4+ T cells.44
Gut microbes also play a role in the metabolism of tryptophan, an essential amino acid that must be
obtained from the diet. Like all amino acids, tryptophan is necessary for protein biosynthesis, but it also
serves as a precursor for serotonin (a neurotransmitter that will be discussed shortly) and it may play a
significant role in the gut – brain axis. Tryptophan is also a precursor for vitamin B3, and the hormone
melatonin among other metabolites. The microbial catabolism of tryptophan by the enzyme indoleamine
2,3-dioxygenase 1 (IDO1) provides anti-inflammatory mechanisms by inducing Tregs through the
activation of aryl hydrocarbon receptor (AhR), a transcription factor that regulates gene expression and
leads to immunomodulation and control of inflammatory processes and epithelial integrity in the gut.45
A recent study demonstrates that metabolic syndrome induced by high-fat diet in mice AhR agonists,
produced by gut microbes, is reduced and negatively impacts the integrity of the intestinal barrier.46 The
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process was mediated by a reduction in the production of Glucagon-like peptide 1 (GLP-1), produced by
intestinal enteroendocrine L-cells through tryptophan catabolism proposed as an anti-diabetic drug.47
Interestingly, the treatment with an analog of GLP-1 in experimental autoimmune encephalomyelitis
(EAE) rats, delays the onset of disease and reduces its severity in a mechanism proposed by the authors
of the study to be dependent on the reduction in oxidative stress.48
Other dietary factors such as vitamin D could be of importance in the context of MS49, since MS
patients show reduced vitamin D levels in serum. Although sun exposure is a factor proposed for such
deficiency, geographical locations with ample exposure to sunlight such as Mediterranean countries still
present MS patients with low vitamin D levels.50 In this context, it is relevant to note that in obese
individuals, low bioavailability of vitamin D is also observed.51 The diminished capacity of vitamin D
availability suggests a dysfunction rather than a low exposure to sun light.
Dietary interventions have been shown to impact the most salient features of CNS inflammatory
demyelination that characterize the animal models of MS. In EAE, axonal damage induced by active
disease induction was significantly affected by the chow used for feeding

52

. In this recent study

investigators compared the progression of EAE and axonal damage in mice fed with conventional (Teklad
7012) or AIN-93M chow. Although the progression of the disease was comparable in mice fed with either
chow the study showed that diet impacted the thickness of axons, showing a reduction in those animals
fed with Teklad 7012 chow.52
Cycles of food intake reduction reduced the severity of disease in C57BL/6 mice, completely in 20%
of the animals tested, when compared to conventional diet.53 In this study 3-day cycles of a fasting
mimicking diet with a low protein and caloric content were administered for 3 days every 7 days starting
a few days after disease onset. The dietary approach reduced significantly the frequencies of
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proinflammatory Th1 and Th17 cells in periphery and proinflammatory cytokines detected in serum,
reduced infiltration of immune cells into the CNS, and had opposite effects in Tregs.
The failure to distinguish between self and non-self is a hallmark of autoimmunity, and it is this
malfunction that mediates the destructive response of immune cells to target otherwise healthy tissues.
In MS, the immune cells target the CNS, and demyelination occurs as a result. Proinflammatory immune
pathways associated to T cell and B cell subsets are detected in the CNS of MS patients. These pathways
are characterized by the secretion of inflammatory mediators such as cytokines and by an increase in
reactive oxygen and nitrogen species, which signal an immunological attack on the myelin which
surrounds neuronal axons, and which promotes astrocyte and microglia activation. The attack results in
neurodegeneration. Within months of the first attack the lesions can be observed by magnetic resonance
imaging (MRI). Although natural remyelination can occur the process becomes less efficient as the disease
progresses.54
Because of the key involvement of proinflammatory responses triggered during MS, it is relevant to
highlight the importance of the gut-associated lymphoid tissue (GALT) since it serves as the main
peripheral immune reservoir of the human body. In the GALT, specialized secondary lymphoid tissues such
as the Peyer’s patches diffuse lymphoid aggregates and mesenteric lymph nodes that are connected to
the lymphatic system, serve as an enhanced area for host-microbe interactions and are essential for
protection against pathogens and to help establish symbiotic relationships with commensal or mutualistic
microbes. T cells are activated in the lymph nodes by antigen presenting cells (APCs) loaded with antigens.
Activation promotes T cell clonal expansion and differentiation of T cells into different subsets.
Differentiation depends on which cytokines are secreted during activation and may also depend on the
nature of the antigen which was presented. Peripheral tolerance mechanisms ensure that the only T cells
which proliferate are the ones that have been appropriately activated through the major
histocompatibility (MHC) – peptide – T cell receptor (TCR) signal, costimulatory signal, and the cytokines,
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and that autoreactive T cells do not proliferate. Tregs also play a major role in peripheral tolerance by
suppressing the proliferation of inflammatory cell subsets such as Th1 and Th17 cells and modulate the
activation state of APCs. As we discuss in the next section, the gut microbiota also plays an essential role
in regulating the balance of inflammatory and immunoregulatory responses. For example, the gut
bacteria Segmented filamentous bacteria (SFB) triggers proinflammatory responses55 while others such
as Bacteroides fragilis induce T cell-mediated tolerogenic responses.56 Thus, changes in the composition
of the gut microbiota causing alterations in the immune homeostasis57, which can then lead to
exacerbated inflammatory diseases.58 Although the exact molecular mechanism by which the gut
microbiota and autoreactive cells is driving MS remains to be elucidated recently published results
propose that it may be through a molecular mimicry process. Molecular mimicry represents a scenario
where an epitope is shared between a microbe and the host which triggers the activation of autoreactive
cells in response to both microbe and target cell.59,60
We next cover the most salient findings that suggest the importance of the balance between proand anti-inflammatory responses triggered by gut microbes, and how this balance can help regulate CNS
inflammatory demyelination.

X.3

Experimental evidence for the gut microbiome and MS connection
The evaluation of the potential impacts of the microbiome on MS began experimentally, using

murine models of the disease. Experimental autoimmune encephalomyelitis (EAE) is a murine disease
characterized by CNS inflammatory demyelination that resembles some of the most prominent features
of the human disease. EAE induced in mice, rats and non-human primates is widely used in academia and
industry to help study CNS inflammation of nucleated cells, gliosis and astrogliosis, demyelination and
natural processes of remyelination, and peripheral immune mechanisms triggered during the disease
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among other topics. In the context of the microbiome, the first studies using EAE were done in mice using
the broad treatment of a mixture of several antibiotics61,62 and the induction of the disease in gnotobiotic
or germ-free (GF) mice. GF animals are maintained free of microbes and show important anatomical and
immunological abnormalities when compared with animals housed conventionally. These differences are
significantly important when considering that in GF mice there is a profound bias in the T helper cell
differentiation pattern within the GALT that results in significantly lower frequency of Th17 cells.63 It has
been postulated that the reduction in Th17 cells, proinflammatory cell subset characterized by the
production of interleukin-17 (IL-17) cytokines, IL-21, IL-22 and granulocyte-macrophage colonystimulating factor (GM-CSF) in response to extracellular pathogens, reduces the susceptibility to disease
in murine models of autoimmunity when compared to conventional mice, such as

diabetes64,

inflammatory bowel disease65, rheumatoid arthritis.66 In the context of MS research, GF mice show
reduced susceptibility to EAE that is induced spontaneously in a transgenic murine model67 and actively
induced with myelin oligodendrocyte glycoprotein 35 - 55 (MOG35-55) in wild-type C57BL/6 EAE.68 A marked
reduction of proliferative responses in MOG-stimulated T cells isolated from TCR-transgenic EAE mice
when compared to WT counterparts suggest that GF conditions impact the ability of autoantigen cells to
proliferate, indicating a role of the microbiome in regulating the frequencies of autoreactive T cells in
molecular mimicry conditions that stimulate autoimmunity.68
The impact of broad alterations of the gut microbiota with antibiotics on the severity of the disease
was described by Yokote and collaborators.61 In their study investigators proposed a mechanism of
protection based on the effects of invariant natural killer (iNK) cells. The effects of Foxp3+CD25+CD4+ Tregs
on the balance between pro- and anti-inflammatory responses altered with antibiotics in EAE mice was
also observed.62 EAE protection with antibiotics was reduced when mice were subjected to CD25
depletion, while the adoptive transfer of Tregs isolated from mice previously treated with antibiotics
reduced the susceptibility to the disease of recipient mice.62 Although the treatment with a mixture of
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broad spectrum antibiotics is not suitable for the treatment of the disease, these studies served as the
foundation for later studies.69,70 In a murine model of autoimmune uveitis, a disease that also has genetic
and environmental factors associated with increased risk, antibiotics reduced the susceptibility by
reducing Th17 cells and increased Tregs. The treatment reduced the frequency of members of Firmicutes
and Bacteroidetes phyla, and class Alphaproteobacteria while Gammaproteobacteria increased.71 Results
suggest that the murine model of CNS demyelinating inflammation affects the overall impact that large
alterations in the microbiome broad alterations of the microbiome, since the treatment does not affect
severity of the disease in the Theiler’s virus model of encephalitis.72
Because of the reduced susceptibility to EAE in GF mice the model has been used to determine the
potential role of individual microbial species, by modulating the severity and progression of the disease.
When GF mice are monocolonized with Segmented filamentous bacteria (SFB), a Gram-positive bacterium
identified as a strong Th17 cell inducer, EAE severity is restored.68 An oral commensal bacterium
exacerbates disease symptoms of EAE, such as Porphyromonas gingivalis73,74 while other gut microbes
such as Bifidobacterium animalis75, Lactobacillus spp.76 and Prevotella histicola77 promote protection.
The common mechanism of action proposed is immunomodulation triggered by an expansion of Tregs
and control of pro-inflammatory responses mediated by Th1 and Th17 cells. Tolerogenic dendritic cells
that could result in Treg polarization and immunosuppressive macrophages induced by the oral treatment
with P. histicola have also been recently documented.77
The studies of the immunomodulatory effects of gut microbial species resulted in the identification
of symbiont factors produced by Bacteroides fragilis. B. fragilis is a Gram-negative bacterium present in
the mammalian gut. Research produced over the last decades indicate that B. fragilis serves as a human
gut symbiont. The bacterium produces 8 different extracellular polysaccharides that are necessary for its
survival within the gut.78 One of these polysaccharides, Polysaccharide A (PSA), promotes tolerogenic
responses triggered by dendritic cells that result in the differentiation of T cells into IL-10-producing T
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cells, with either Foxp3+ or Foxp3- phenotypes. PSA is a zwitterionic molecule that is recognized by
dendritic cells79 and plasmacytoid dendritic cells80 by recognition with Toll-like receptor 2 (TLR2). It is
presented to T cells through an MHC class II-dependent mechanism.56 The monocolonization of GF with
PSA-producing B. fragilis results in the reinstatement of immune homeostasis in the gut of the Th2-biased
mice.81 PSA has been shown to be protective against Helicobacter hepaticus model of experimental
colitis79, asthma82, and EAE.83-85 The protective effects of PSA are believed to be dependent on the
induction of IL-10 producing Tregs86, IL-10 producing Foxp3- CD4+ T cells79,82,87, and IL-10 producing CD39+
T cells.84,85 Although no evidence is currently available about the potential protective effects of PSA in
humans, in vitro data using peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals
indicates that PSA also exerts immunomodulation.88 PSA exposure to human naïve CD4+ T cells and
dendritic cells promotes T cell differentiation into Tregs.88 Interestingly, the Tregs induced have a CD39+
phenotype, a Treg subpopulation that appears dysfunctional in suppressing the proliferation of
inflammatory T cells and the production of IL-17 in MS populations.89 When circulating healthy human
FoxP3+ CD4+ T cells were co-cultured with PSA-exposed dendritic cells the expression levels of CD39 were
enhanced, as well as the capacity of the Tregs to produce IL-10.88 These cells were immunosuppressive,
as evidenced by the results obtained in vitro assays where Tumor Necrosis Factor – alpha (TNF-)
production by lipopolysaccharide (LPS)-stimulated monocytes was evaluated.88 In CD4+ T cells isolated
from MS patients, PSA exacerbates IL-10 production.90 The expression levels of Foxp3 observed in MS
cells stimulated with PSA were significantly higher than those observed in healthy cells stimulated with
the polysaccharide.90
Although the highlighted results suggest that microbial antigens are mechanistically responsible for
the immunomodulatory effects observed, important effects in neural and endocrine pathways and
metabolism, by the production of key metabolites such as SCFAs have also been observed when altering
the microbiome. Some of these factors directly influence the progression of the biology within the CNS
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and disease outcomes and can be modified with diet, such as SCFAs, as previously described. The
Hypothalamic Pituitary Adrenal (HPA) axis mediates stress responses by producing hormones such as
adenocorticotrophic hormone (ACTH) and corticosteroids. It has been shown that inflammation is
another modulator of HPA function and that HPA-secreted hormones impact intestinal barrier integrity
and the composition of the microbiome.91 Reciprocally, gut microbes control the metabolism of
neurotransmitters such as serotonin92 and gamma-Aminobutyric acid (GABA).93 Furthermore, the effects
of intestinal microbes on the neural system can be direct, as PSA produced by B. fragilis has the ability to
activate intestinal neurons.94 In the context of the neural system the importance of the vagus nerve should
be addressed since it constitutes the most direct pathway of interaction within the gut/brain axis. Vagal
nerve neurons express TLRs and it has been shown that microbial metabolites such as SCFAs can activate
the vagal nerve.95 Thus, experimental evidences suggest that there are multiple potential avenues of
interaction between the gut microbiome and the CNS. This likely multifactorial interaction combined with
the individual’s genetic makeup and the extreme variety of the overpopulated gut ecosystem result in a
tremendous challenge when evaluating the potential impact of gut microbes on the disease.
Another aspect to consider when evaluating the results obtained from experimental models of
disease is whether the link between the gut microbiome and diseases are reciprocal. As murine studies
performed in GF conditions suggest, the lack of microbes affect morphology75, angiogenesis76, and
remarkably the integrity of the intestinal barrier.96 This is of particular interest because the disruption of
the intestinal barrier is also observed in response to disease induction. During EAE induced actively with
self-antigens and passively by the adoptive transfer of autoreactive T cells isolated from EAE mice, a
disruption in the intestinal epithelium barrier is observed.97 The effects observed are based on the loss of
tight junction protein integrity, causing what it is called “leaky gut”. The treatment with probiotics 96 and
SCFA98 have been shown to reduce intestinal permeability and leaky gut. Whether the intestinal
permeability is enhanced during MS is still unknown although a recent pilot study suggest that it might be
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the case.99,100 One of the potential mediators for increased permeability is TNF-, enhanced in the CNS of
EAE and MS patients.101 TNF- is a molecular mediator of the genetic gene expression patterns that result
in changes in the zonulin pathway and tight junction expression levels102, which indicates CNS
inflammation could potentially impact the intestinal permeability. The impact of disease on the gut
microbiota of mice was recently evaluated by our laboratory. Results show that when EAE is induced in
non-obese diabetic (NOD) mice a long-term, biphasic, disease occurs in approximately 75% of mice.70 We
used this long-term model of disease in order to compare the composition of the gut microbiota of EAE
with control.70 We observed that those mice that would develop a more severe form of disease had a
microbiota composition significantly different than the one isolated from control mice. The statistical
analysis performed indicated that the differences were observed at early stages of disease (day 14 and
30) while at late stages of disease (day 58) the differences observed were not statistically significant. We
next questioned whether the alteration of the gut microbiota with antibiotics at different stages of disease
would affect the progression of EAE. Interestingly, only those mice subjected to early treatment (from day
0 to 14) showed reduced EAE severity while mice treated from days 30 to 44 and from 70 to 84 showed
no changes in the EAE clinical score curves.70 Based on the results obtained we concluded that disease
induction affects the composition of the microbiota, which suggest a bidirectional flow of events between
the gut microbiota and the disease, and that early interventions that impact the microbiota could result
in later protective effects against the progression of the disease.
Taken together, the earliest and most recent literature suggest that gut microbes and factors
produced by gut microbes have the capacity to control the immune system in such remarkable way that
the effects modulate the severity of murine models of CNS inflammatory demyelination. However, is the
gut microbiome of MS patients significantly different than the microbiome of healthy individuals?
Moreover, if differences are observed, are those changes sufficient to functionally affect the onset or the
progression of disease? These aspects will be covered in the next section of the chapter.
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X.4

The gut microbiome of MS
Over the last decade the number of published works that use murine models of disease to research

if there is a multifactorial association between the gut microbiome and MS, have significantly increased.103
Furthermore, clinical investigations performed in the context of other autoimmune related diseases
indicate that the gut microbiome of individuals suffering from conditions such as inflammatory bowel
disease104, rheumatoid arthritis105, diabetes106, psoriasis107, systemic lupus erythematosus108,
neuromyelitis optica (NMO)109, Parkinson’s disease110, Alzheimer’s disease and others harbor a distinct
microbiota when comparing it with the composition of healthy individuals111. The most commonly
proposed hypothesis is that an altered microbiome can then significantly influence immune, metabolic
and/or neuroendocrine homeostasis, resulting in pathologic pathways that lead to disease, this imbalance
of the gut microbiota is a process globally known as dysbiosis.
Despite the recent efforts, signature, disease-specific, microbiomes have not been yet identified.
Although the term enterotype was proposed for a given cluster of individuals sharing a microbiome
pattern identified by specific taxa that serve as markers

112

others question its validity since it may be

dependent on the statistical approach used to define it, as reviewed by Costea et al.113 These clinical
studies require in-depth control of the conditions of the experiment, collection, storage and processing of
the samples, DNA extraction and manipulation and appropriate protocols for sequencing, meta-analysis
and statistical analysis, all of which can affect the results if not monitored properly.114,115 Furthermore, it
is important to consider cofounding factors that affect the composition of the microbiota, as those
described previously in the chapter.
Results obtained in GF EAE mice suggest that dysbiotic alterations of the gut microbiome mediated
by genetic and environmental cofounders could impact immune homeostasis and the function of the
immune system’s ability in regulating autoimmunity through peripheral tolerance. Our immune system
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uses central and peripheral control mechanisms to minimize the deleterious consequences of allowing
circulating autoreactive T and B cells. Central tolerance responses are triggered during T cell development
in the thymus and B cell development in the bone marrow, while peripheral tolerance responses are
triggered largely in part by regulatory T cells. As summarized previously, changes in the microbiome could
impact the presence and function of proinflammatory cell subsets, which in the context of disease would
exacerbate immunopathological pathways that lead to demyelination, oligodendrocyte cell killing, axonal
loss and neuronal death. Concomitantly, the changes in the microbiota composition could result in
reduced regulatory T cell frequencies and dysfunction. In MS patients, peripheral tolerance mechanisms
based on Treg function appear to be disrupted and are unable to control the proliferation of autoreactive
T cells sufficiently.89,116-118 Another mechanism of action linked to dysbiosis is that during MS the intestinal
barrier permeability might be disrupted
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. The leaky gut effect would result in increases in the

concentration of microbial inflammatory factors such as endotoxin and microbial translocation to deep
tissues which promotes a state of chronic inflammation that has been observed in diet-induced obesity119,
a scenario covered later in this section.
When comparing the gut microbiome of MS patients with healthy individuals, the overall structure
remains unaltered however, significant changes in the relative abundances of specific taxa are
observed.120-124 Similar Alterations on the microbiome have also been described in pediatric MS.125,126 Even
with variability in the data, these results taken together suggest that during MS, even at early stages of
life, the gut microbiome differs from the microbiome isolated from healthy individuals. Microbiome
changes have been described for other diseases of the CNS such as Parkinson’s disease110,127,128, and for
patients suffering from NMO.59 In NMO patients, an intestinal overabundance of Clostridum perfringens
was observed and a mechanism of molecular mimicry between bacterial adenosine triphosphate (ATP)
binding cassette transporters and an epitope of aquaporin-4 was proposed based on in vitro proliferation
assays with Th17 cells.109 Curiously, C. perfringens type B was previously isolated from the intestines of an
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MS patient.129 A more recent study shows that a CD4+ T cell clone that was isolated from the cerebrospinal
fluid of one MS patient harbors a TCR specific for an epitope of the enzyme GDP-L-fucose synthase,
expressed in human cells of multiple tissues, including white and grey matter of the CNS of postmortem
samples of MS patients. Investigators showed that CD4+ T cells isolated from approximately 40% of the
MS and CIS. Samples from MS patients tested reacted to GDP-L-fucose synthase and differentiated into
IFN--producing Th1 cells. Since the enzyme is also used by members of the gut microbiota, the study
evaluated cross-reactivity of bacterial homologues of GDP-L-fucose synthase with MS CD4+ T cell clones.60
More functional studies are required in order to assess the biological relevance of the observed
changes on the microbiome and to better determine the impact of these changes on disease onset,
progression and severity. Two recent studies provided further evidence for the potential functional impact
that altered microbiota might have on MS. Both studies performed using GF mice, evaluated the effects
of the fecal microbiota transplantation (FMT) on the incidence and severity of EAE in mice.123,124 The
mechanism of action of the microbiota transplanted was proposed to be immunomodulatory, by impacts
on the regulatory of IL-10-producing Tregs and IL-10-producing CD4+ T cells.
Evaluated together the results discussed above would indicate that the microbiota and changes on
its composition is an essential component in the homeostatic balance of the immune system. As a result,
one could hypothesize that environmental factors capable of altering specific microbial taxa of the
intestine could, at least in part, be responsible for proinflammatory pathways associated with disease.
The experimental evidence highlights the complex multifactorial and reciprocal nature of the gut and CNS
disease interactions. Despite the complexity of such interactions, it is essential to consider specific
mechanisms of action in order to advance the search for novel therapeutics. One possible mechanism of
action is the increase in the intestinal permeability that is observed in different models of disease and also
in obesity which can be regulated by caloric restriction.130 A detrimental impact on the integrity of the
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intestinal epithelium could result in chronic inflammation caused by microbial and translocation and the
crossing of microbial components such as endotoxin.
When comparing the BMI that women reported to have at 18 years of age11, BMI at ages 7 to 1312
and findings of two case-control studies with BMI data131 the risk for MS is two-fold enhanced in
individuals who are obese during adolescence.2 The association between early life obesity and MS
incidence is strongest when BMI > 27.9,131 Another relevant risk factor proposed for MS is vitamin D
deficiency, which could be a cofounding factor when considering MS in previously obese patients, as
obesity can have an affect by impacting the bioavailability of vitamin D.51 The studies also indicate that
elevated BMI is also positively associated with pediatric MS. Because pediatric MS and MS patients both
show significant differences in specific taxa of the gut microbiota when compared with the microbiota of
healthy individuals, and diet is a critical environmental factor that regulates BMI and obesity, it is plausible
to consider diet as a mechanism by which MS progression and even onset can be regulated. Furthermore,
obesity and chronic inflammation are also positively associated as evident by increases in
proinflammatory cytokines and inflammatory pathways and decreases in immunoregulatory function of
Tregs that has been observed experimentally and clinically in animal models. Furthermore, Macrophages
isolated from diet-induced obese mice showed a proinflammatory gene expression profile characterized
by increased expression of TNF- and inducible NO synthase (iNOS) as opposed to macrophages isolated
from lean mice.132 LPS of Gram-negative bacteria has been linked to diet-induced obesity and metabolic
disease characterized by glucose intolerance.119 The study also indicates that the composition of the
microbiota of diet-induced obese mice was significantly different to the microbiota of lean mice, and that
diet-induced obese mice had increased intestinal permeability, inflammation and increased expression
associated with oxidative stress. The serum of diet-induced obese animals showed a significant increase
in the endotoxin levels, suggesting the impact of increased intestinal permeability on chronic
inflammation.119 Murine models also show that a westernized diet promotes significant changes in the
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composition of the gut microbiota and that the transplantation of obese microbiota feces also transfers
an obese phenotype to the GF recipient mice.133 Interestingly, GF mice show a reduced susceptibility to
diet-induced obesity and glucose intolerance.64,134 Early studies done in monozygotic and dizygotic twins
also indicated that the microbiota of obese individuals is significantly different to lean individuals.135 The
presence of a chronic, low-grade inflammation in obese individuals is postulated based on the prolife of
proinflammatory cytokines quantified in human adipose tissue136 and serum.137,138
As it was previously discussed the microbiome and the endocrine system appears to be reciprocally
associated. In this context, the hormone leptin, is produced by adipose cells in response to food intake.139
As an anorexigenic factor, leptin interacts with the HPA and controls food intake. Mice deficient in lectin
production are obese and show a microbiota with a composition significantly different to the composition
of wild type counterparts.140 High leptin levels correlates with EAE onset141, and having a significant
deficiency in leptin production renders mice resistant to EAE. However, the treatment of EAE mice with
neutralizing anti-leptin antibodies protects mice against disease.142 Clinically, increased levels of leptin
have also been observed in brains of MS biopsies when compared to control samples.143
This section has summarized some of the most relevant publications that suggest the association
between the microbiome and MS. Since diet composition is one of the most relevant modifying factors
on the microbiome, we will next discuss the therapeutic potential of dietary interventions against MS.

X.5

Dietary-microbiome interventions in MS
As recently revised by Thompson and colleagues, there are now 13 different disease-modifying

medications which are currently available for the treatment of MS. These treatments target inflammation,
peripherally or within the CNS, with neuroprotection being a possible indirect outcome.2 The risks
associated with these treatments are unfortunately directly proportional to their effectiveness and higher
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efficacy indicates the likelihood of more serious complications 2. Since the first drug for the treatment of
relapsing MS was approved in 1995, a lot of progress has been made in searching for better therapies, but
safer and more protective options are still in high demand. Furthermore, almost all approved drugs target
relapsing forms of MS, which indicates that progressive MS is still a clinically unmet challenge.
In this section we will solely focus on dietary interventions as a potential avenue for treating MS.
Studies evaluating the effects of dietary habits on MS risk support the premise that diet is an
environmental factor to be considered144,145, and the impact of diet and dietary habits has been tested in
murine models of CNS inflammatory demyelination, such as EAE.44,52,53 As recently reviewed by Riccio and
colleagues the experimental and clinical evidence summarized in previous sections suggest that the
association between diet, the gut microbiome and MS is at least in part mediated by low-grade
inflammation.49 More recent studies also suggest the possibility of molecular mimicry induced in response
to epitopes shared between the gut microbiota and target cells. The effects of intestinal permeability on
these processes as well as direct effects on neuroendocrine systems also need further attention.100 A
dietary intervention could possibly target potentially deleterious changes in the gut microbiota, intestinal
permeability and inflammation, and may also affect metabolism including energy efficiency.
The significance of the recent findings that correlate the gut microbiome and MS is highlighted by
the numerous recent studies designed to evaluate impact of diet on disease. A pilot study performed in
RRMS patients studied the effects of diet on relapse rates and Expanded Disability Status Scale (EDSS)
scores as well as microbiota composition in individuals that based on their dietary habits of the previous
12 months were divided in two groups, one of patients (n = 10) following a high-vegetable/low-protein
diet and a second group following a westernized diet (n = 10). The study reported changes on specific taxa
such as an increase in the relative abundances of members of the family Lachnospiraceae in individuals
following high-vegetable/low-protein diet that correlated positively with reductions in proinflammatory
cell profiles and increases in anti-inflammatory cells, including Tregs.146 Moreover, the pilot study,
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although based on a limited number of patients, indicated a beneficial impact on relapse rates and EDSS
in RRMS patients.146
The supplementation of the diet has been tested in MS patients. A 30-month pilot study tested the
effects of omega-3, and omega-6 polyunsaturated fatty acids on the progression of the disease.147 The
results provided preliminary evidence for the beneficial impact of the dietary intervention when
comparing relapse rates per year. Riccio and colleagues performed a 7-month intervention in MS patients
(both relapsing and progressive MS forms) fed with a semi-vegetarian calorie restricted diet, which
included several supplements such as vitamin D.50 Treated patients were compared with placebo controls.
The conclusions of the study suggest that the intervention reduced inflammatory parameters, such as
serum metalloproteinase-9 levels.50
The impact of diet and dietary habits has been tested in murine models of CNS inflammatory
demyelination, such as EAE. Cycles of reducing food intake, lessened the severity of disease in C57BL/6
mice, completely reversed all symptoms in 20% of the animals tested, when compared to conventional
diet.53 In this study 3-day cycles of a fasting mimicking diet (FMD) with a low protein and low caloric
content were administered for 3 days every 7 days starting a few days after disease onset. The dietary
approach reduced significantly the frequencies of proinflammatory Th1 and Th17 cells in periphery and
proinflammatory cytokines detected in serum, reduced infiltration of immune cells into the CNS, and had
opposite effects in Tregs. Similarly, a continuous ketogenic diet also conferred protection against the
disease. The dietary intervention also impacted the metabolic system as evidenced by the increase in
corticosterone levels found in the serum of mice. Interestingly the diet also offered neuroprotective
effects that resulted from increased oligodendrocyte precursor cell regeneration which caused
remyelination in vivo. The positive impact of the diet was also observed therapeutically in mice with
already established severe EAE.53 Furthermore, investigators performed a 6-month long pilot experiment
on 60 RRMS patients that were separated into three groups. Individuals were either in the control diet
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group (n=20), given a ketogenic diet (n=20) or given a variant of the fasting mimicking diet which was
administered for 7 days and followed by a Mediterranean like diet for the rest of the 6 months. Despite
the limitations of a pilot study the results indicated the potential safety of dietary interventions and
showed beneficial effects in patients that were treated with one of the dietary interventions when
compared to no diet change at all.53
The effects of calorie restriction has been already tested in MS patients.148 The study was performed
in 36 patients diagnosed with RRMS that were subjected to either one of three dietary interventions based
on the calorie restriction: 22% daily reduction in energy needs, 75% reduction 2 days per week and 0%
reduction 5 days per week), and 0% reduction in energy needs. Weight loss was not significant among
groups. The dietary interventions did not improve significantly the functional assessment of MS (FAMS)
score nor fatigue or sleep quality. When associated with patients that had lost weight the calorie
restriction showed a significant increase in emotional well-being scores.148 The study also indicated that
the intervention was not associated with adverse effects.
The importance of diet in the severity of diagnosed MS was further evaluated by the same group of
investigators using a questionnaire-based analysis of the nutritional habits of almost 7,000 patients.149
Overall, patients using a high quality diet and healthy lifestyles showed a 20% reduction in the likelihood
of scoring high at Patient-Determined Disease Steps (PDDS) when compared with individuals exposed to
low quality diets. High quality diets were considered those rich in fruits, vegetables, legumes, whole grains
and low in red meat and in sugars from sweets and beverages. The diets considered of highest quality and
healthy lifestyles were associated with a reduction in the likelihood of suffering from more severe forms
of depression, but not with pain, fatigue, or cognitive symptoms. However, an increased intake of some
nutritional types such as whole grains and total dairy showed a reduced likelihood of developing severe
versus mild disability than those with low intake of those foods.149 The study suggests that the
consumption of high quantities of some dietary factors could be associated with lower disability scores.
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A recent EAE study by Kap and colleagues performed in marmosets provides direct evidence for the
protective effects that a dietary intervention could have in CNS inflammatory demyelinating diseases such
as MS.150 In adult marmosets EAE is induced actively with recombinant human MOG1-125 and incomplete
Freund’s adjuvant. Investigators used eight twin pairs of marmosets to compare the incidence and
severity of disease induced after the long-term treatment with conventionally used water-based
supplement (WBS) and with a new yogurt-based supplement (YBS), with enhanced concentrations of
yogurt, vitamin D, lemon juice, carrot juice, and oatmeal, among others. The incidence of disease was
reduced from 100% in WBS to 65% in YBS and reversed to 100% when returned to WBS supplementation.
The reverse in disease incidence was accompanied by increased neuroinflammation and demyelination,
changes in gene expression patterns and inflammatory pathways, as well as changes in the composition
of the gut microbiota of the marmosets. The yogurt-based supplement was associated with significant
reductions in IL-17A and IFN- levels quantified in supernatants of MOG-stimulated T cells isolated from
mesenteric lymph nodes. Interestingly, the changes observed in the composition of the microbiota were
only apparent after EAE induction and the activation of the immune responses that characterize the
disease, which suggests a bidirectional interplay between the microbiota and disease151 and a critical
impact of diet. Further mechanistic studies are needed to unravel the hypothesized beneficial impact of
diet on disease incidence and progression.

X.6

Concluding remarks
Recent experimental and clinical evidence indicates that during MS the composition of the intestinal

microbiota differs from that of healthy animals and individuals in specific taxa. Furthermore, some recent
works show that the qualitative and quantitative changes might be accompanied by functional effects
that regulate the extent of experimental disease. Since diet is a major modulator of the microbiota
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composition and function and because early obesity constitutes a risk factor for MS, it is plausible to
propose a dietary intervention that targets the gut microbiota to help treat this devastating disease of the
CNS. Although more and larger clinical studies are needed to fully evaluate the impact of diet and dietary
changes on MS pathology and progression, recent experimental data does suggest that a dietary
intervention could be used to reduce the severity of the disease. This approach would constitute a
significant advance in the quality of life for those suffering from MS, as it would most likely have less
adverse effects when compared to the currently approved and prescribed disease-modifying MS drugs on
the market. Nevertheless, the study of diet and its impact on the gut microbiota as a possible avenue for
novel therapeutic options in MS still carries significant challenges, such as cofounding factors that modify
the microbiota including the host’s genetics and disease, as well as inter and intra-individual variability.
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